Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Kedudukan dalam Saham #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicelโ€”a specialized cell therapyโ€”has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Harga Saham
$0.0327
Disegerakkan terakhir: 2025-06-17
Modal Pasaran
$4.34M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
IL
Perdagangan Gamida Cell Ltd. (GMDA)

Kategori

Sejarah dividen untuk Gamida Cell Ltd. (GMDA)
Gamida Cell Ltd. (simbol saham: GMDA) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk Gamida Cell Ltd. (GMDA) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE